The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Four-year minimum follow-up of ongoing patients (pts) with chronic-phase chronic myeloid leukemia (CP-CML) in a phase 1 trial of ponatinib (PON).
 
Moshe Talpaz
Consulting or Advisory Role - ARIAD; Novartis; Pfizer
Research Funding - ARIAD; Incyte; Novartis; Pfizer; Sanofi
Travel, Accommodations, Expenses - ARIAD; Incyte; Novartis; Pfizer
 
Jorge E. Cortes
Consulting or Advisory Role - ARIAD; Bristol-Myers Squibb; Novartis; Pfizer
Research Funding - ARIAD; Bristol-Myers Squibb; Novartis; Pfizer; Teva
 
Hagop M. Kantarjian
Research Funding - Amgen (Inst); ARIAD (Inst); Bristol-Myers Squibb (Inst); Delta-Fly Pharma (Inst); Novartis (Inst); Pfizer (Inst)
 
Neil P. Shah
Research Funding - ARIAD; Bristol-Myers Squibb; Daiichi Sankyo; Pfizer; Plexxikon
 
Dale L. Bixby
No Relationships to Disclose
 
Ian Flinn
Stock and Other Ownership Interests - RainTree Oncology Services
Research Funding - ARIAD (Inst)
 
Thomas J O'Hare
No Relationships to Disclose
 
Simin Hu
Employment - ARIAD
Stock and Other Ownership Interests - ARIAD
 
Victor M. Rivera
Employment - ARIAD
Stock and Other Ownership Interests - ARIAD
 
Timothy Piers Clackson
Employment - ARIAD
Stock and Other Ownership Interests - ARIAD
 
Maureen G Conlan
Employment - ARIAD
Stock and Other Ownership Interests - ARIAD
 
Frank G. Haluska
Employment - ARIAD
Stock and Other Ownership Interests - ARIAD
 
Brian J. Druker
Stock and Other Ownership Interests - Blueprint Medicines; CTI; Cylene; Lorus; MolecularMD
Honoraria - Agios
Consulting or Advisory Role - Ambit BioSciences; AstraZeneca; Blueprint Medicines; CTI; Cylene; D3 Oncology Solutions; Gilead Sciences; Lorus; MolecularMD; Roche
Research Funding - ARIAD; Bristol-Myers Squibb; Novartis; Oncotide Pharmaceuticals
Patents, Royalties, Other Intellectual Property - I receive royalties from Dana-Farber Cancer Institute (DFCI), who has an exclusive commercial license with Millipore (formerly Upstate Biotechnology) for monoclonal antiphosphotyrosine antibody 4G10, which I developed while employed at DFCI.; Oregon Health & Science University patents from which I have or will receive royalties as an inventor: o #843 Mutated ABL Kinase Domains (has been licensed to ARIAD Pharmaceuticals, Inc.; Array BioPharma, Inc.; Curis, Inc.; MolecularMD Corporation; Pfiz
Travel, Accommodations, Expenses - Blueprint Medicines; Gilead Sciences
 
Michael W.N. Deininger
Honoraria - ARIAD; Bristol-Myers Squibb; Incyte; Novartis; Pfizer
Consulting or Advisory Role - ARIAD; Bristol-Myers Squibb; Incyte; Novartis; Pfizer
Research Funding - Bristol-Myers Squibb (Inst); Celgene (Inst); Incyte (Inst); Novartis (Inst)
Expert Testimony - Bristol-Myers Squibb
Travel, Accommodations, Expenses - ARIAD; Bristol-Myers Squibb; Novartis; Pfizer
 
Michael J. Mauro
Honoraria - ARIAD; Bristol-Myers Squibb; Novartis; Pfizer
Consulting or Advisory Role - ARIAD; Bristol-Myers Squibb; Novartis; Pfizer
Research Funding - Novartis